Medicine and Dentistry
Radiation Therapy
100%
Non Small Cell Lung Cancer
91%
Lung Cancer
55%
Proton Therapy
42%
Overall Survival
41%
Neoplasm
35%
Immunotherapy
29%
Progression Free Survival
26%
Diseases
26%
Pneumonia
22%
Pneumonectomy
18%
Non-Small Cell Lung Cancer
18%
Lung
17%
Recurrent Disease
17%
Metastatic Carcinoma
15%
Hazard Ratio
15%
Primary Tumor
15%
Stereotactic Body Radiation Therapy
14%
Chemoradiotherapy
13%
Surgery
13%
Esophageal Cancer
13%
Immune Checkpoint Inhibitor
12%
Immunity
12%
Drug Megadose
12%
Nanoparticle
11%
Systemic Therapy
10%
Adverse Event
10%
Raman Spectrometry
10%
Intensity Modulated Radiation Therapy
10%
Immune Response
9%
Malignant Neoplasm
9%
Systemic Disease
7%
Long Term Survival
7%
Diagnosis
7%
Epidermal Growth Factor Receptor
7%
T Cell
7%
Low Drug Dose
7%
Clinical Trial
7%
Proportional Hazards Model
7%
Odds Ratio
7%
Interstitial Lung Disease
7%
Cardiotoxicity
6%
Immune-Related Adverse Events
6%
Re-Irradiation
6%
Phase II Trials
6%
Patient Selection
6%
Dyspnea
6%
Arm
6%
Health Care Cost
6%
Radioimmunotherapy
6%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
80%
Overall Survival
34%
Stereotactic Ablative Radiotherapy
28%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
28%
Progression-free Survival
27%
Proton Beam Therapy
27%
Oligometastatic
26%
Tumor
24%
Pneumonitis
23%
Immune Checkpoint Inhibitors
21%
Radiation Therapy
20%
NBTXR3
19%
Anti-PD-1
18%
Nanoparticles
18%
Primary Tumor
18%
Immunoradiotherapy
15%
Local Consolidative Therapy
15%
Lung Cancer
14%
Hazard Ratio
13%
Concurrent Chemotherapy
13%
Proton
12%
Chemoradiation
12%
Lung Cancer Model
11%
Immune-related Adverse Events
11%
Early-stage Lung Cancer
11%
Single Institution
11%
Multivariable
11%
Checkpoint Inhibitors
11%
Durvalumab
10%
Chemotherapy
10%
Proton Therapy
10%
Phase II Trial
10%
Postoperative Radiotherapy
10%
Intensity-modulated Radiation Therapy
9%
Survival Outcomes
9%
Local Control
9%
Lung
9%
Secondary Tumor
9%
Pulmonary Resection
8%
Confidence Interval
8%
Metastatic Disease
8%
Immunosuppressive Agents
7%
Recurrent Non-small Cell Lung Cancer
7%
Immune System
7%
Non-small Cell Lung Cancer Patients
7%
High Risk
7%
Radiation Dose
7%
Odds Ratio
7%
Low-dose Radiation
7%
Interstitial Lung Disease
7%